Professor Michael H. Gleb (born 1957) is an American biochemist and chemist specializing in enzymes and particularly those of medical significance.

Granted an American Cancer Society postdoctoral fellowship, he then investigated mechanism-based inactivators of serine proteases and developed fluorinated ketones as tight-binding inhibitors of several classes of proteases, working with Robert H. Abeles at Brandeis University.

In order to investigate enzymatic processes of biomedical importance, the Gelb laboratory employs a variety of methods from molecular and cellular biochemistry as well as synthetic organic chemistry.

[4] Routine newborn screening of lysosomal storage diseases using technology developed in the Gelb laboratory was brought into use in New York state in 2006 .

His current research interests include: 1) Studying the function and regulation of a group of enzymes called phospholipase A2 that are involved in lipid mediator biosynthesis related to inflammation; 2) Anti-malaria and anti-trypanosome drug discovery; 3) New technology for the newborn screening of enzyme deficiency diseases including lysosomal storage diseases.